Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.

Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, Kopf S, Weycker D, Kirchgaessler KU, Ryerson CJ.

Respiration. 2018 Jul 19:1-9. doi: 10.1159/000489668. [Epub ahead of print]

PMID:
30025392
2.

The Management of Patients With Idiopathic Pulmonary Fibrosis.

Spagnolo P, Tzouvelekis A, Bonella F.

Front Med (Lausanne). 2018 Jul 2;5:148. doi: 10.3389/fmed.2018.00148. eCollection 2018. Review.

3.

[DGP Interstitial Lung Disease Patient Questionnaire].

Kreuter M, Ochmann U, Koschel D, Behr J, Bonella F, Claussen M, Costabel U, Jungmann S, Kolb M, Nowak D, Petermann F, Pfeiffer M, Polke M, Prasse A, Schreiber J, Wälscher J, Wirtz H, Kirsten D.

Pneumologie. 2018 Jun;72(6):446-457. doi: 10.1055/s-0044-100207. Epub 2018 Feb 21. German.

PMID:
29466814
4.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.

PMID:
29414827
5.

Phenotypes of organ involvement in sarcoidosis.

Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O'Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane MP, O'Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J.

Eur Respir J. 2018 Jan 25;51(1). pii: 1700991. doi: 10.1183/13993003.00991-2017. Print 2018 Jan.

PMID:
29371378
6.

German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2018 Feb;72(2):155-168. doi: 10.1055/s-0043-123035. Epub 2018 Jan 16.

7.

European Respiratory Society International Congress 2017: highlights from the Clinical Assembly.

Kahn N, Mekov E, Fregonese L, Andrianopoulos V, Franssen FME, Grgic A, Coolen J, Bonta PI, Gompelmann D, Annema JT, Faverio P, Bonella F, Daines L, Pinnock H, Kocks J, Herth F.

ERJ Open Res. 2018 Jan 10;4(1). pii: 00134-2017. doi: 10.1183/23120541.00134-2017. eCollection 2018 Jan.

8.

Serum YKL-40 in workers at an indium-tin oxide production facility - Reply.

Bonella F, Costabel U; all co-authors.

Respirology. 2018 Mar;23(3):342. doi: 10.1111/resp.13237. Epub 2017 Dec 15. No abstract available.

PMID:
29243860
9.

Patients with IPF and lung cancer: diagnosis and management.

Tzouvelekis A, Spagnolo P, Bonella F, Vancheri C, Tzilas V, Crestani B, Kreuter M, Bouros D.

Lancet Respir Med. 2018 Feb;6(2):86-88. doi: 10.1016/S2213-2600(17)30478-2. Epub 2017 Dec 11. No abstract available.

PMID:
29241977
10.

Therapeutic targets in idiopathic pulmonary fibrosis.

Kolb M, Bonella F, Wollin L.

Respir Med. 2017 Oct;131:49-57. doi: 10.1016/j.rmed.2017.07.062. Epub 2017 Aug 1. Review.

PMID:
28947042
11.

Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.

Maher TM, Molina-Molina M, Russell AM, Bonella F, Jouneau S, Ripamonti E, Axmann J, Vancheri C.

BMC Pulm Med. 2017 Sep 15;17(1):124. doi: 10.1186/s12890-017-0468-5.

12.

Coagulation factor XII regulates inflammatory responses in human lungs.

Hess R, Wujak L, Hesse C, Sewald K, Jonigk D, Warnecke G, Fieguth HG, de Maat S, Maas C, Bonella F, Preissner KT, Weiss B, Schaefer L, Kuebler WM, Markart P, Wygrecka M.

Thromb Haemost. 2017 Oct 5;117(10):1896-1907. doi: 10.1160/TH16-12-0904. Epub 2017 Aug 17.

PMID:
28816340
13.

Differential diagnosis of granulomatous lung disease: clues and pitfalls: Number 4 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.

Ohshimo S, Guzman J, Costabel U, Bonella F.

Eur Respir Rev. 2017 Aug 9;26(145). pii: 170012. doi: 10.1183/16000617.0012-2017. Print 2017 Sep 30. Review.

14.

Idiopathic pleuroparenchymal fibroelastosis (PPFE) - A case study of a rare entity.

Boerner EB, Costabel U, Wessendorf TE, Theegarten D, Bonella F.

Rev Port Pneumol (2006). 2017 Nov - Dec;23(6):352-355. doi: 10.1016/j.rppnen.2017.06.006. Epub 2017 Aug 3.

15.

Timing of onset affects arthritis presentation pattern in antisyntethase syndrome.

González-Gay MA, Montecucco C, Selva-O'Callaghan A, Trallero-Araguas E, Molberg O, Andersson H, Rojas-Serrano J, Perez-Roman DI, Bauhammer J, Fiehn C, Neri R, Barsotti S, Lorenz HM, Doria A, Ghirardello A, Iannone F, Giannini M, Franceschini F, Cavazzana I, Triantafyllias K, Benucci M, Infantino M, Manfredi M, Conti F, Schwarting A, Sebastiani G, Iuliano A, Emmi G, Silvestri E, Govoni M, Scirè CA, Furini F, Lopez-Longo FJ, Martínez-Barrio J, Sebastiani M, Manfredi A, Bachiller-Corral J, Sifuentes Giraldo WA, Cimmino MA, Cosso C, Belotti Masserini A, Cagnotto G, Codullo V, Romano M, Paolazzi G, Pellerito R, Saketkoo LA, Ortego-Centeno N, Quartuccio L, Batticciotto A, Bartoloni Bocci E, Gerli R, Specker C, Bravi E, Selmi C, Parisi S, Salaffi F, Meloni F, Marchioni E, Pesci A, Dei G, Confalonieri M, Tomietto P, Nuno L, Bonella F, Pipitone N, Mera-Valera A, Perez-Gomez N, Gerzeli S, Lopez-Mejias R, Matos-Costa CJ, Pereira da Silva JA, Cifrian J, Alpini C, Olivieri I, Blázquez Cañamero MÁ, Rodriguez Cambrón AB, Castañeda S, Cavagna L; AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):44-49. Epub 2017 Jul 26.

16.

[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017].

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2017 Jul;71(7):474. doi: 10.1055/s-0043-115504. Epub 2017 Jul 5. German. No abstract available.

PMID:
28679139
17.

Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.

Bonella F, Long X, He X, Ohshimo S, Griese M, Guzman J, Costabel U.

Respirology. 2017 Oct;22(7):1371-1378. doi: 10.1111/resp.13082. Epub 2017 May 31.

18.

[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017].

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2017 Jul;71(7):460-474. doi: 10.1055/s-0043-106160. Epub 2017 May 30. German. Erratum in: Pneumologie. 2017 Jul;71(7):474.

PMID:
28558396
19.

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.

Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler KU, Costabel U.

Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12.

20.

FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis.

Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Shime N, Bonella F, Guzman J, Costabel U, Kohno N.

Respir Med. 2017 Feb;123:105-109. doi: 10.1016/j.rmed.2016.12.007. Epub 2016 Dec 22.

PMID:
28137485
21.

Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis.

Long X, He X, Ohshimo S, Griese M, Sarria R, Guzman J, Costabel U, Bonella F.

Eur Respir J. 2017 Feb 23;49(2). pii: 1501924. doi: 10.1183/13993003.01924-2015. Print 2017 Feb.

22.

Clinical significance of the "galaxy sign" in patients with pulmonary sarcoidosis in a Japanese single-center cohort.

Koide T, Saraya T, Tsukahara Y, Bonella F, Börner E, Ishida M, Ogawa Y, Hirukawa I, Oda M, Shimoda M, Ohkuma K, Fujiwara M, Takata S, Yokoyama T, Kurai D, Ishii H, Goto H, Takizawa H.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 7;33(3):247-252.

PMID:
27758990
23.

Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis.

Wuyts WA, Spagnolo P, Bonella F, Yserbyt J, Verleden GM.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1033-1034. No abstract available.

PMID:
27739891
24.

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.

Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M.

Thorax. 2017 Feb;72(2):148-153. doi: 10.1136/thoraxjnl-2016-208819. Epub 2016 Oct 5.

25.

[German Validation of the "King's Brief Interstitial Lung Disease (K-Bild) Health Status Questionnaire"].

Kreuter M, Birring SS, Wijsenbeek M, Wapenaar M, Oltmanns U, Costabel U, Bonella F.

Pneumologie. 2016 Nov;70(11):742-746. Epub 2016 Sep 21. German.

PMID:
27652583
26.

Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters J, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Orphanet J Rare Dis. 2016 Aug 31;11(1):115. doi: 10.1186/s13023-016-0497-9.

27.

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.

Bonella F, Kreuter M, Hagmeyer L, Neurohr C, Keller C, Kohlhaeufl MJ, Müller-Quernheim J, Milger K, Prasse A; German Nintedanib Compassionate Use Consortium.

Respiration. 2016;92(2):98-106. doi: 10.1159/000448288. Epub 2016 Aug 20.

28.

[Epidemiology and Clinical Presentation of Sarcoidosis].

Costabel U, Wessendorf TE, Bonella F.

Klin Monbl Augenheilkd. 2017 Jun;234(6):790-795. doi: 10.1055/s-0042-105569. Epub 2016 Jul 25. Review. German.

PMID:
27454307
29.

A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters JC, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Chest. 2016 Jul;150(1):251-3. doi: 10.1016/j.chest.2016.04.030. No abstract available.

30.

European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity.

Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, Wuyts W.

Eur Respir J. 2016 Jul;48(1):283-4. doi: 10.1183/13993003.00604-2016. No abstract available.

31.

New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?

Wijsenbeek M, van Manen M, Bonella F.

Curr Opin Pulm Med. 2016 Sep;22(5):434-41. doi: 10.1097/MCP.0000000000000294. Review.

PMID:
27333428
32.

MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis.

Bonella F, Long X, Ohshimo S, Horimasu Y, Griese M, Guzman J, Kohno N, Costabel U.

Orphanet J Rare Dis. 2016 Apr 23;11:48. doi: 10.1186/s13023-016-0430-2.

33.

How to handle IPF--the new Portuguese consensus document.

Costabel U, Bonella F.

Rev Port Pneumol (2006). 2016 Mar-Apr;22(2):70-2. doi: 10.1016/j.rppnen.2016.03.001. No abstract available.

34.

Pulmonary alveolar proteinosis: another autoimmune disease associated with sarcoidosis?

Boerner EB, Costabel U, Wessendorf TE, Theegarten D, Hetzel M, Drent M, Bonella F.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):90-4.

PMID:
27055841
35.

MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?

Mölleken C, Poschmann G, Bonella F, Costabel U, Sitek B, Stühler K, Meyer HE, Schmiegel WH, Marcussen N, Helmer M, Nielsen O, Hansen S, Schlosser A, Holmskov U, Sorensen GL.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):41-50.

PMID:
27055835
36.

An Important Step Forward, but Still a Way to Go.

Wuyts WA, Bonella F, Costabel U, Cottin V, Kreuter M, Poletti V, Spagnolo P.

Am J Respir Crit Care Med. 2016 Feb 1;193(3):340-1. doi: 10.1164/rccm.201509-1763LE. No abstract available.

PMID:
26829426
37.

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.

Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P.

Biomed Res Int. 2015;2015:329481. doi: 10.1155/2015/329481. Epub 2015 Dec 8. Review.

38.

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.

Bonella F, Stowasser S, Wollin L.

Drug Des Devel Ther. 2015 Dec 14;9:6407-19. doi: 10.2147/DDDT.S76648. eCollection 2015. Review.

39.

Pulmonary alveolar proteinosis in a cat.

Szatmári V, Teske E, Nikkels PG, Griese M, de Jong PA, Grinwis G, Theegarten D, Veraa S, van Steenbeek FG, Drent M, Bonella F.

BMC Vet Res. 2015 Dec 9;11:302. doi: 10.1186/s12917-015-0613-4.

40.

European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers.

Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, Wuyts W.

Eur Respir J. 2016 Feb;47(2):597-606. doi: 10.1183/13993003.01204-2015. Epub 2015 Nov 19.

41.

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.

Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA.

Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5.

42.

New guideline on treatment of idiopathic pulmonary fibrosis.

Spagnolo P, Bonella F, Maher TM.

Lancet Respir Med. 2015 Sep;3(9):e31-e32. doi: 10.1016/S2213-2600(15)00322-7. No abstract available.

PMID:
26380887
43.

Hypersensitivity Pneumonitis: A Comprehensive Review.

Spagnolo P, Rossi G, Cavazza A, Bonifazi M, Paladini I, Bonella F, Sverzellati N, Costabel U.

J Investig Allergol Clin Immunol. 2015;25(4):237-50; quiz follow 250. Review.

44.

GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders.

Griese M, Zarbock R, Costabel U, Hildebrandt J, Theegarten D, Albert M, Thiel A, Schams A, Lange J, Krenke K, Wesselak T, Schön C, Kappler M, Blum H, Krebs S, Jung A, Kröner C, Klein C, Campo I, Luisetti M, Bonella F.

BMC Pulm Med. 2015 Aug 12;15:87. doi: 10.1186/s12890-015-0083-2.

45.

[Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis].

Behr J, Bonella F, Bonnet R, Gläser S, Grohé C, Günther A, Koschel D, Kreuter M, Kirsten D, Krögel C, Markart P, Müller-Quernheim J, Neurohr C, Pfeifer M, Prasse A, Schönfeld N, Schreiber J, Wirtz H, Witt C, Costabel U.

Pneumologie. 2015 Aug;69(8):455-8. doi: 10.1055/s-0034-1392602. Epub 2015 Jul 30. German.

PMID:
26227628
46.

Facts and promises on lung biomarkers in interstitial lung diseases.

Campo I, Zorzetto M, Bonella F.

Expert Rev Respir Med. 2015 Aug;9(4):437-57. doi: 10.1586/17476348.2015.1062367. Epub 2015 Jul 4. Review.

PMID:
26146183
47.

Diagnosis of Sarcoidosis.

Wessendorf TE, Bonella F, Costabel U.

Clin Rev Allergy Immunol. 2015 Aug;49(1):54-62. doi: 10.1007/s12016-015-8475-x. Review.

PMID:
25779004
48.

Update on therapeutic management of idiopathic pulmonary fibrosis.

Tzouvelekis A, Bonella F, Spagnolo P.

Ther Clin Risk Manag. 2015 Mar 3;11:359-70. doi: 10.2147/TCRM.S69716. eCollection 2015. Review.

49.

A pilot study: a combined therapy using polymyxin-B hemoperfusion and extracorporeal membrane oxygenation for acute exacerbation of interstitial pneumonia.

Itai J, Ohshimo S, Kida Y, Ota K, Iwasaki Y, Hirohashi N, Bonella F, Guzman J, Costabel U, Kohno N, Tanigawa K.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 5;31(4):343-9.

PMID:
25591146
50.

MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis.

Horimasu Y, Ohshimo S, Bonella F, Tanaka S, Ishikawa N, Hattori N, Kohno N, Guzman J, Costabel U.

Respirology. 2015 Apr;20(3):439-44. doi: 10.1111/resp.12466. Epub 2015 Jan 8.

Supplemental Content

Loading ...
Support Center